Immunotherapy

Steering committee:

Gunnar Kvalheim, leader
Svein Dueland
Gustav Gaudernack
Arne Kolstad
Olav Engebråten


Aim:
The hospital has an extensive research program on different types of in-house developed cancer vaccines and antibody based immunotherapy approaches. The aim of these projects is to:

1. Develop new cancer vaccines and immuno-gene-therapy approaches.
2. Study T-cell responses following different immunotherapy approaches and identify and characterise novel cancer antigens recognised by patients immune system ( antibodies and T-cells).
3. Initiate clinical vaccine trials on synthetic tumour specific peptides and gene modified dendrite cells
   
4. Perform clinical trials employing systemic treatment with tumour associated monoclonal antibodies alone or conjugated with radioisotopes or toxins.